ADAMTS15
| ADAMTS15 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | ADAMTS15, ADAM metallopeptidase with thrombospondin type 1 motif 15 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 607509; MGI: 2449569; HomoloGene: 8610; GeneCards: ADAMTS15; OMA:ADAMTS15 - orthologs | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
ADAMTS15 is a protein-coding gene that belongs to the ADAMTS family. The ADAMTS family, which stands for A Disintegrin-like and Metalloproteinase with Thrombospondin motifs. This family consists of enzymes involved in extracellular processes.[5] These enzymes play roles in modifying the extracellular matrix (ECM) which is important for maintaining tissue structure and function.
ADAMTS15 protein participates in extracellular matrix (ECM) remodeling, a process that is important in cancer and normal biological functions.[6] It is involved in the regulation of proteoglycans within the ECM which can suppress tumor growth.[6] The ADAMTS15 protein functions as a secreted enzyme, meaning it is located outside the cell where it can interact with its surroundings.
Structure
[edit]ADAMTS15 has several functional domains, giving it a complex protein structure. One of its main features is the metalloprotease domain, which is responsible for cleaving and breaking down proteins.[6] ADAMTS15 requires zinc for its enzymatic activity. This zinc ion stabilizes its active site to allow catalytic activity.[5]
In addition to the metalloprotease domain, it also contains thrombospondin motifs that contribute to its structure, function and its ability to interact with the extracellular matrix.[6] The protein is produced in an inactive form and becomes active after proteolytic cleavage.[6] This step is essential because the enzyme only functions when needed and prevents the breakdown of the extracellular components.
Function
[edit]ADAMTS15 functions as a protease that breaks down proteins.[6] It primarily acts in the extracellular matrix, where it targets proteoglycans such as Versican.[7] Versican is an important structural component of the ECM and plays a role in maintaining tissue hydration and organization.[7] By cleaving Versican and other substrates, ADAMTS15 plays a role in ECM remodeling. This remodeling changes the environment surrounding cells, which can affect how they behave. It plays a role in cell signaling, migration, and adhesion.[7] These processes are important for normal tissue development, but when they are not properly regulated, they can also contribute to disease. As a result, ADAMTS15 influences cell signaling, migration, and adhesion.[7] For example, when the ECM is modified, cells can become less tightly attached and more capable of moving, which is a key factor during normal processes like tissue development and wound healing.[7] In addition, changes in the ECM can affect how molecules interact with cells, which may alter pathways that control cell growth and differentiation.[7] These processes are important for maintaining normal tissue function, but when they are not properly regulated, they can also contribute to disease. Disruption of ECM remodeling has been associated with conditions such as cancer, where changes in cell adhesion and migration can increase tumor progression and metastasis.
Cancer
[edit]ADAMTS15 has been studied for its role in cancer and is generally thought to act as a tumor suppressor.[8] Research shows that when its expression is increased, there is a decrease in cell proliferation, cancer cell migration, and survival in prostate cancer cells.[8] These effects depend on its enzymatic activity, since the inactive form doesn't work the same way. When this protein is lost or mutated, tumor growth has been linked to increase.[8]
The function of ADAMTS15 is also linked to the cleavage of proteoglycans such as Versican, which can influence tumor cell behavior. Because of this, ADAMTS15 has the potential to be used as both a biomarker and a therapeutic target in cancer.[6] The extracellular matrix (ECM) helps support tissue structure and can act as a barrier, but it can also be remodeled. Changes in ECM remodeling have been linked to worse outcomes in cancers like melanoma, breast, and prostate cancer. [6] These changes can impact processes including cell adhesion, migration, proliferation, and angiogenesis.
Extracellular matrix remodeling plays an important role in cancer progression because it affects how tumor cells grow and spread. By modifying components of the ECM, ADAMTS15 can change the environment around cancer cells, making it less favorable for tumor growth. This supports its role as a tumor suppressor.[6] Changes in ECM structure can also affect angiogenesis, which is the formation of new blood vessels that supply tumors with nutrients.[8] Through these affects, ADAMTS15 may indirectly limit tumor growth and metastasis.
Inflammation/Cardiovascular
[edit]ADAMTS15 has also been linked to inflammatory pathways, especially through changes in its expression during disease. Since Inflammation plays a role in many conditions, including cardiovascular disease, this connection is important. Some studies suggest that ADAMTS15 may help regulate these pathways, which could support tissue balance and reducing damage during disease.[9]
Metabolism of Adipose
[edit]This protein has also been studied in metabolic processes, particularly in adipose tissue. Loss of this protein has been shown to increase the browning of white fat, which affects energy metabolism.[10] The browning of white fat occurs when energy storing fat cells begin to take on characteristics of energy burning cells.[10] This change can increase metabolic activity and heat production. Because of this, ADAMTS15 may play a role in regulating energy balance and metabolic health.[10]
Genetics/Expression
[edit]ADAMTS15 is encoded by a gene located on chromosome 11 in humans. It is expressed in multiple tissue types, suggesting it plays a role in a variety of biological processes. [11] Expression levels of ADAMTS15 can change under different disease conditions, particularly in cancer and inflammatory states.[11] Mutations in this gene may lead to a loss of normal protein function, which can disrupt its role in regulating extracellular matrix components.[11] Understanding how ADAMTS15 expression is regulated may provide insight into its role in both normal physiology and disease.
Clinical Significance
[edit]ADAMTS15 is clinically significant due to its involvement in several disease processes. In cancer, loss or inactivation of ADAMTS15 has been associated with tumor progression, supporting its role as a tumor suppressor.[7] Studies have also linked genetic inactivation of this metalloprotease to cancers such as colorectal cancer.[7]
References
[edit]- ^ a b c GRCh38: Ensembl release 89: ENSG00000166106 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000033453 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ a b Apte, Suneel S. (2004-06-01). "A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family". The International Journal of Biochemistry & Cell Biology. Modulatory Adhesion Molecules in Tissue Homeostasis. 36 (6): 981–985. doi:10.1016/j.biocel.2004.01.014. ISSN 1357-2725. PMID 15094112.
- ^ a b c d e f g h i Dancevic, Carolyn M.; Fraser, Fiona W.; Smith, Adam D.; Stupka, Nicole; Ward, Alister C.; McCulloch, Daniel R. (2013-12-27). "Biosynthesis and Expression of a Disintegrin-like and Metalloproteinase Domain with Thrombospondin-1 Repeats-15: A NOVEL VERSICAN-CLEAVING PROTEOGLYCANASE *". Journal of Biological Chemistry. 288 (52): 37267–37276. doi:10.1074/jbc.M112.418624. ISSN 0021-9258. PMC 3873579. PMID 24220035.
- ^ a b c d e f g h Binder, Marley J.; McCoombe, Scott; Williams, Elizabeth D.; McCulloch, Daniel R.; Ward, Alister C. (2020-04-28). "ADAMTS-15 Has a Tumor Suppressor Role in Prostate Cancer". Biomolecules. 10 (5): 682. doi:10.3390/biom10050682. ISSN 2218-273X. PMC 7277637. PMID 32354091.
- ^ a b c d Viloria, Cristina G.; Obaya, Alvaro J.; Moncada-Pazos, Angela; Llamazares, María; Astudillo, Aurora; Capellá, Gabriel; Cal, Santiago; López-Otín, Carlos (2009-06-01). "Genetic Inactivation of ADAMTS15 Metalloprotease in Human Colorectal Cancer". Cancer Research. 69 (11): 4926–4934. doi:10.1158/0008-5472.CAN-08-4155. hdl:10651/30664. ISSN 0008-5472. PMID 19458070.
- ^ Zuo, Bo; Zhu, Sha; Wang, Guisong; Li, Zhengpeng (2023-05-10). "Transcriptome analysis reveals ADAMTS15 is a potential inflammation-related gene in remote ischemic postconditioning". Frontiers in Cardiovascular Medicine. 10 1089151. doi:10.3389/fcvm.2023.1089151. ISSN 2297-055X. PMC 10206167. PMID 37234367.
- ^ a b c Choi, Min Ji; Mukherjee, Sulagna; Yun, Jong Won (2021-04-01). "Loss of ADAMTS15 Promotes Browning in 3T3-L1 White Adipocytes via Activation of β3-adrenergic Receptor". Biotechnology and Bioprocess Engineering. 26 (2): 188–200. doi:10.1007/s12257-021-0036-y. ISSN 1976-3816.
- ^ a b c "ADAMTS15 ADAM metallopeptidase with thrombospondin type 1 motif 15 [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2026-04-18.